A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Condition:   TNBC - Triple-Negative Breast Cancer Interventions:   Drug: Camrelizumab Plus Chemotherapy and Famitinib;   Drug: Camrelizumab Plus Chemotherapy Sponsor:   Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials